#truvada prep dosage

[genericforce-blog]

What is PrEP?

PrEP means Pre-Exposure Prophylaxis. It’s the use of anti-HIV medicines to keep HIV negative people from becoming infected. PrEP Pills is approved by the FDA and has been shown to be safe and effective at preventing HIV infection.

Truvada is currently the only drug approved for use as PrEP HIV Pills. Truvada prep is a single pill that is a combination of two anti-HIV drugs, tenofovir, and emtricitabine. Truvada is the brand name for PrEP, but generic forms of PrEP HIV are available, which contain the same active drugs.

PrEP is different from PEP (Post-exposure prophylaxis), which is an emergency treatment for HIV taken after possible exposure to the virus. PrEP greatly reduces the risk of HIV. PrEP Medicine for HIV is a powerful prevention tool and can help reduce anxiety and stress for people at risk of contracting HIV.

PrEP Medication for HIV:

Tenvir EM Tablet

Viraday Tablet

Tenvir 300 Mg

Tafero Em Tablet

Tavin Em

Where can I Buy PrEP Medicine?

We are GenericForce, one of the most trusted generic drugstores in the world today. From allover the world come to us to buy all kinds of medicines and healthcare products. https://www.genericforce.com/

[himsedpillsreview]

Treating HIV Infection with Tenvir EM Tablet

Tenvir-EM tablet (Tenofovir / Emtricitabine) is an antiviral medicine used to treat patients suffering from human immunodeficiency virus (HIV). It operates by stopping the reproduction of virus cells allowing the immune system to naturally control the infection. 

What is Tenvir-EM (Tenofovir / Emtricitabine)?

Tenvir EM Tablet is a generic version of Truvada. Tenvir 300 mg prevents the multiplication of HIV virus in human cells, thus stopping HIV virus from producing new infections. Tenvir-EM Tablet is a combination drug consisting of two antiretroviral drugs, Tenofovir and Emtricitabine, used in the treatment of HIV. It can be used as pre-exposure prophylaxis against HIV. Visit this site www.himsedpills.com for more information.

What is Tenvir EM prescribed for?

HIV infection:

Tenvir-EM is used in the treatment of Human Immunodeficiency Virus (HIV) infection.

Pre-exposure prophylaxis:

This medication is used in combination with safe-sex practices to reduce the risk of sexually acquired HIV infection in adults at high risk.

How should I use Tenvir-EM?

Always follow your physician's instructions while using the Tenvir L Tablets to get the safest and most effective results from treatment. One tablet is usually taken once daily. As HIV treatment, Truvada must be used in combination with other HIV medicines. As PrEP, Truvada should be used in combination with risk-reduction counseling, correct and consistent condom use, regular HIV testing, and treatment of other sexually transmitted infections.

How Tenvir-Em Tablet Works?

Tenvir-EM Tablet is a combination of two anti-HIV medicines Emtricitabine and Tenofovir disoproxil fumarate. They prevent HIV from multiplying, thereby reducing the amount of virus in your body.

Basic facts about HIV

People with HIV can enjoy a long and healthy life by taking antiretroviral treatment, which is effective and available to all.

Regular testing for HIV is important to know your status. HIV is found in semen, blood, vaginal and anal fluids, and breastmilk.

Using external (or male) condoms or internal (or female) condoms during sex is the best way to prevent HIV and other sexually transmitted infections.

If you’re pregnant and living with HIV, the virus in your blood could pass into your baby’s body during birth or afterward through breastfeeding. Taking HIV treatment and becoming undetectable eliminates this risk.

Stages of HIV Infection

Weight loss

Chronic diarrhea

Night sweats

Fever

Persistent cough

Mouth and skin problems

Regular infections

Serious illness or disease.

Dosage of Tenvir EM Tablet?

Adult Dose: One tablet once a day with or without food. Each tablet contains 300 mg tenofovir disoproxil fumarate + 200 mg emtricitabine.

What are the side effects of Tenvir-EM?

Headaches

Dizziness

Nausea or diarrhea

Depression

Mild skin irritation

Changes in location or shape of body fat

Tenvir-Em Tablet Related Warnings?

Pregnancy:

Tenvir-EM Tablet is generally considered safe to use during pregnancy.

Driving:

Tenvir-EM Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.

Kidney:

Tenvir-EM Tablet should be used with caution in patients with kidney disease. Dose adjustment of Tenvir-EM Tablet may be needed. Please consult your doctor.

The Best Way to Buy Tenvir EM tablet?

Tenofovir is the treatment of serious hepatitis b virus infection and HIV attacks. Tenvir EM is two antiretroviral drugs namely emtricitabine and tenofovir, which are only effective against RNA viruses such as Human beings Immunodeficiency Virus (HIV). 

[hivmeetpostives]

One Pill A Day May Keep HIV Away

The following article One Pill A Day May Keep HIV Away was first published on: HIV Meet Positives Blog

If you are at risk of being infected with HIV, then the University of Arizona Campus Health Service has a drug that will help protect you from this risk. In 2012, the drug, named Truvada, became the first drug to be approved by the FDA in the reduction of risk associated with HIV infection.

Truvada is a combination of tenofovir disoproxil and emtricitabine and a form of pre-exposure prophylaxis, which is also known as PrEP. Cesar Egurrola, lead clinical coordinator at the UA Department of Medicine’s Petersen HIV Clinic, said when a PrEP medication is taken daily by HIV-negative patients, it prevents the transmission of HIV.”

This is especially useful to people who are at risk of infection and though they will have to be tested for HIV regularly, using the drug significantly lowers the infection risk.

“Patients who use PrEP must also undergo routine HIV and STD screenings and regularly visit their PrEP provider while on the medication. There is a similar method of using medication, called post-exposure prophylaxis or PEP, which helps prevent HIV transmission after a person is exposed to it. PEP is most often used after someone may have been exposed to HIV through sexual contact, sexual assault or from exposure to blood, often through needles. If PrEP can be compared to ‘the pill,’ PEP could be compared to ‘Plan B,’ with the exception that, for PEP, the 28-days course of treatment needs to be completed. And there is no weight maximum for PEP efficacy.”

Though the drug is effective, there are some requirements that need to be adhered to. Taking the PrEP drug is a daily affair. Apart from taking the medication daily, it is important that you take the medication 72 hours prior to the HIV exposure for effectiveness. This means that the PrEP and PEP users will have to carefully follow a dosage to be safe.

Both regimens need to be taken daily to provide maximal effectiveness. When taken daily, PrEP has a 92 percent success rate in the prevention of HIV transmission. Per the CDC, PEP is very effective in the prevention of transmission of HIV, but not 100 percent.”

Rising STD Cases

It is important to mention that the use of PrEP and PEP does not protect you from other sexually transmitted diseases and unwanted pregnancies. This is an important point because there is a rise in STD infection cases.

PrEP and PEP only protect against HIV. We continue to see high rates of Chlamydia and have seen more syphilis than in past years. According to the most recent Sexually Transmitted Disease Surveillance report by the Centers for Disease Control and Prevention in 2017, rates of STDs have been increasing across the country.

The report showed that over 1.7 million cases of Chlamydia in the U.S. were reported in 2017, an increase of 6.9 percent from the previous year. Reported cases of gonorrhea totaled over 555,600, which was over an 18 percent increase from 2016 and an increase of a little over 75 percent from a record low in 2009. The CDC report showed rates of syphilis rose 10.5 percent from 2016 to 2017, and 87.7 percent of those reported cases were men. Men make up the majority of people in Arizona who have HIV, according to the 2018 Arizona HIV/AIDS Epidemiology Supplemental Report from the Arizona Department of Health Services.”

Access To PEP and PrEP

People are becoming aware of these drugs and this is in some way helping lower the rate of infection. Though there are no massive campaigns through media channels to create awareness of the drugs, word of mouth is during quite well in spreading the news especially among students.

Word of mouth is an effective tool to encourage our students to come in to Campus Health to start PrEP and PEP, or even simply to ask questions, allowing them to become better informed about their options. Students have the opportunity to get the medications at reduced prices, and some are even able to get them without paying out-of-pocket.

There are patient-assistance programs and grants available that can offset the price of the medications. We utilize pharmacies that are well-versed in navigating these programs in order to provide our students with the lowest cost possible, regardless of insurance coverage or lack thereof.”

It is important to protect yourself when HIV is involved. You can always use protection and combine it with PEP and PrEP to ensure that the risk of infection is significantly lowered. For those living with HIV, the best option is to use a HIV dating site where HIV singles are looking for interesting singles like you. HIV dating has been around for a while and is an effective way to reduce cases of new infections.

[techsciresearch]

United States Pre-Exposure Prophylaxis Market to Grow with an Impressive CAGR until 2026 | TechSci Research

Increasing awareness about HIV/AIDS is driving the growth of United States Pre-Exposure Prophylaxis (PrEP) Market, in the forecast period, 2022-2026.

According to TechSci report on, “United States Pre-Exposure Prophylaxis (PrEP) Market By Drug Type (Truvada v/s Descovy), By Route of Administration (Oral v/s Topical), By Region, Competition Forecast & Opportunities, 2026”, United States pre-exposure prophylaxis (PrEP) market has shown promising growth in historical years until 2020 and is expected to continue its growth in upcoming forecast years 2021 to 2026. The United States pre-exposure prophylaxis (PrEP) market owes its growth to the factors like growing awareness about precaution against HIV viral infection and preventive therapeutics.

The surging demand for the effective precautionary methods or therapeutic products like PrEP drugs for the patients under the risk of contracting HIV infection in future is driving the growth of the United States pre-exposure prophylaxis (PrEP) market in the upcoming five years.

Also, rapidly increasing instances of HIV among the MSM population of the country have scared the population and the government of the country to a large extent thus the population is inclined toward regular checkups and diagnostic tests that can help in deciding the population for the preventive treatment thus supporting the growth of the United States pre-exposure prophylaxis (PrEP) market in the next five years.

Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on "United States Pre-exposure prophylaxis (PrEP) Market"

https://www.techsciresearch.com/report/united-states-pre-exposure-prophylaxis-market/8124.html

Additionally, increasing MSM population of the country is further substantiating the growth of the United States pre-exposure prophylaxis (PrEP) market in the future five years. The MSM population is highly susceptible to HIV infectious diseases and are supporting the market growth in the future. Private fundings, and governmental aids with favorable schemes are supporting the robust growth of the United States pre-exposure prophylaxis (PrEP) market in the forecast period.

The United States pre-exposure prophylaxis (PrEP) market segmentation is based on drug type, route of administration, competitional landscape, and regional distribution. Based on drug type, the market is further bifurcated into Truvada and Descovy. Truvada is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on the account of its high adoption and increased demand since the drug is marketed since early 2019.

Also, higher efficiency and reduced risk of acquiring HIV/AIDS infection comparatively is anticipated to support the growth of the Descovy drug type and thus support the growth of the United States pre-exposure prophylaxis (PrEP) market in the next five years. Truvada is a combination of two drugs, tenofovir disoproxil and emtricitabine. Truvada is a fixed dose of combination of antiretroviral medication that has proven effect on the treatment and prevention of HIV virus.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8124

Customers can also request for 10% free customization on this report.

The drug is administered along with the recommendation of following safer sex practices thus increasing awareness among the population. Tenofovir alafenamide is available in the market under the brand name of Descovy. It is a Hepatitis B virus inhibitor that also acts against HIV viral infection.

On the basis of route of administration, the market segments are defined as oral, and topical. Oral administration of the drugs in anticipated to hold the largest revenue shares of the market and dominate the market segment in the next five years on the account of availability of the drug in pill form.

Also, oral administration is more convenient for daily/ regular administration. Maintaining the dosage is also favorable for oral route of administration and thus supports the growth of the sub-segment and drives the growth of the United States pre-exposure prophylaxis (PrEP) market in the upcoming five years.

A partial list of major market players of the United States pre-exposure prophylaxis (PrEP) market includes:

Gilead Sciences, Inc.

Teva Pharmaceuticals USA, Inc.

Merck & Co., Inc.

Cipla Inc

Bristol-Myers Squibb Company

Genentech, Inc

These market players along with new market entrants, are focused on extensive research and bringing innovative and advanced products. Technologically advanced manufacturing of the pharmaceutical products and therapeutic processes would aid in decreasing the cost of the production and aid the players in managing their investments. Moreover, initiatives from the government and private fundings would support the United States pre-exposure prophylaxis (PrEP) market growth indirectly.

Press Release: https://www.techsciresearch.com/news/6705-united-states-pre-exposure-prophylaxis-market.html

“Young population in the United States is getting highly aware of the increasing instances of HIV virus and their awareness is boosting the growth of the United States pre-exposure prophylaxis (PrEP) market in the upcoming five years. Increasing research and innovative therapeutic product development is further driving the growth of the United States pre-exposure prophylaxis (PrEP) market in the future five years. Through researched studies and surveys authoritative bodies are creating awareness among black and Hispanic population about them being more susceptible to HIV infection and further aiding the market growth in next five years,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United States Pre-Exposure Prophylaxis (PrEP) Market By Drug Type (Truvada v/s Descovy), By Route of Administration (Oral v/s Topical), By Region, Competition Forecast & Opportunities, 2026” has evaluated the future growth potential of United States pre-exposure prophylaxis (PrEP) market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States pre-exposure prophylaxis (PrEP) market.

Browse Related Projects:

United States Smart Hospitals Market By Component (Hardware, Software System, Services) By Technology (Cloud Computing, Artificial Intelligence, Wearable Technologies, Others) By Connectivity (Wired v/s Wireless) By Application (Remote Medicine Management, Medical Connected Imaging, Medical Assistance, Electronic Health Record, Others) By Services Offered (General Services, Specialty, Super Specialty), By Region, Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/united-states-smart-hospitals-market/8037.html

Vietnam Telemedicine Market By Component (Services, Software, Hardware), By Deployment Mode (Cloud v/s On-Premises), By Type (Tele-Hospitals, mHealth, Tele-Homes), By Technology (Store & Forward, Real Time, Others), By Application (Tele-Psychiatry, General Consultations, Tele-Radiology, Tele-Pathology, Others), By End User (Payer, Provider, Patients), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/vietnam-telemedicine-market/7899.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[siglerprescriptiondrugcards]

Emtricitabine plus Tenofovir Disoproxil Fumarate

Brand Name: Truvada

Common Dosage Forms:

Tablets: 100 mg emtricitabine with 150 mg tenofovir disoproxil fumarate, 133 mg emtricitabine with 200 mg tenofovir disoproxil fumarate, 167 mg emtricitabine with 250 mg tenofovir disoproxil fumarate, 200 mg emtricitabine with 300 mg tenofovir disoproxil fumarate

FDA Indications/Dosages:

Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection: Adult and pediatric patients 12 years of age and older (>35 kg): One regular dose (200 mg emtricitabine) tablet daily with ot without food. Pediatric patients weighing at least 17 kg: One low dose (<200 mg emtricitabine) tablet daily with or without food.

Indicated in combination with safer sex practices for HIV-1 preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg.

Dosage in renal impairment (CrCL 30-49 mL/min): 1 regular dose tablet orally every 48 hours with or without food.

Monitor: CD4+ cell count, BMD, RFT, LFT

Pharmacology/Pharmacokinetics: Emtricitabine undergoes phosphorylation by cellular enzymes to form emtricitabine 5′-triphosphate. This metabolite inhibits the activity of the HIV-1 RT by competing with the natural substrate deoxycytidine 5′-triphosphate. Incorporation of emtricitabine 5′-triphosphate into the viral DNA results in chain termination. Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. It is ultimately converted to tenofovir diphosphate, through hydrolysis and phosphorylation, where it inhibits the activity of HIV-1 RT by competing with deoxyadenosine 5′-triphosphate for incorporation into DNA. It ultimately causes chain termination. Excretion occurs by the kidneys via glomerular filtration and active tubular secretion.

Drug Interactions: May increase the plasma levels of didanosine. Atazanavir and lopinavir/ritonavir may increase tenofovir concentrations. Drugs eliminated by active tubular secretion may increase concentrations of both tenofovir and emtricitabine. Avoid coadministration with lamivudine-containing products. Avoid coadministration with adefovir due to enhanced nephrotoxicity.

Contraindications/Precautions: Contraindicated in patients allergic to any component. Use with caution in patients with known risk factors for liver disease due to the risk of severe hepatomegaly. May cause lactic acidosis. Use caution in patients coinfected with hepatitis B since exacerbation of hepatitis B may occur upon discontinuation of this drug. Do not use in patients with severe renal impairment (CrCL <30 mL/min). Renal function should be determined before initiation of therapy and periodically thereafter. Tenofovir disoproxil fumarate may cause a decrease in bone mineral density (BMD). BMD should be evaluated periodically. Pregnancy Category B.

Adverse Effects: The most common adverse effects are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. Other adverse effects are fat redistribution (around the midsection) and skin discoloration (palms and soles).

Patient Consultation:

May be taken with or without food.

If you miss a dose, take it as soon as you remember. If it is close to the time of your next dose, skip the missed dose and carry on with your normal dosing schedule. Do not double doses.

Call your healthcare provider if you experience any symptoms of lactic acidosis (very weak, unusual muscle pain, breathing trouble, stomach pain with nausea or vomiting, fast or irregular heartbeat, dizziness, coldness in extremities).

Call your healthcare provider if you experience any symptoms of liver dysfunction (yellow eyes or skin, dark urine, light-colored stools, anorexia, stomach pain, or nausea).

This medication does not prevent you from transmitting HIV-1 to other people. Do not share needles, personal items that have blood or body fluids on them, and use barrier protection (condoms) during sex.

[nzprep]

And so it begins

Today there was a parcel at my door. In it is my first tranche of generic #truvada, prescribed by my local doctor, ordered from Swaziland and delivered via India and Singapore. The packaging was amateurish, but the contents are real.

I will take my first dosage tomorrow. There are a few reasons why I’m going to give #PREP a go.

First, I want to understand the embodied experience of taking it daily.

Second, friends who are overseas are already reporting that condoms are quickly becoming a rarity in place where PREP uptake is high. I still want to use condoms--lots of other STIs to be caught and there’s always a chance of a new pathogen to appear. Kind of like HIV did in the 1970s.

Third, here in NZ PREP is only funded for the “bad gays”, those who get fucked bareback by guys who are poz and not on treatment or with guys they don’t know their HIV status. That means the rest of us either pay silly US big pharma prices for named Truvada in NZ...or import our own generic version, legally. I wanted to see what it’s like to navigate that process. I am used to bureaucracy and I have the resources to pay for my own PREP. 

Finally, I am in my heart a communitarian kind of sodomite. The shared ethic of care from my queer adolescences (my 20s, in other words) has served me well. So if my being on PREP helps end the HIV epidemic, awesome.

This blog is a place for me to produce a discourse about my PREP experience and related musings.

[rabbitears91]

The year is almost over, this is so crazy. 

This year has been crazy in no shortage of the imagination. It’s been scary, rough, surprising, etc. I’ve passed my one year since phalloplasty, earned my Master’s degree, obtained full time employment (I don’t start for another 6 weeks) and started on prep. All of these things have been incredibly meaningful to me for various reasons, most of which I cant talk about IRL.

My life has been pretty normal in many ways since surgery but there have also been moments where I didn’t know if I’d make it to where I am now. I didn’t always voice those things because I know folks worry and this has been my life since I can ever remember so...only in hindsight do things seem crazy, scary, dangerous. 

I’ve had many moments where balancing responsibilities and personal relationships have been exhausting but that’s really just life. I didn’t have a stable housing situation for much of 2017 so I needed to do what would generate money. I’d want to just go to Starbucks or Del Taco for some chili cheese fries, you know? I was trying to wrap up my MA thesis for much of 2017 and stress eating is expensive. 

I had a falling out with a close supporter (we have since sorted our differences out) and in a way, it was what I needed to knock that fucking thesis out once and for all. I had my defense and the eventually it was May and I had my degree!!!

When I was kicked out of a relative’s house I recall being told my education would be something I wouldnt obtain. I totally fucking did it though! I have my MA and nobody or no situation can ever take that knowledge and journey away from me. I undoubtedly need a break from school for the time being but no regrets, surprisingly. I didnt think I would say that when I was trekking through the chapters, the edits, the comments from my committee but here we are :)

My thesis focused on religion, sex, sexuality, identity, etc which was super appropriate for the year and my own sex life. Being further and further out from phalloplasty has really put me out there sexually. I’ve had a lot of sex this year. While it hasn’t all been amazing or even alright, I never in a million years thought this could be my life, should I choose or need it to be so. If my life were different financially, I dont know if this would be my life but today it is, yesterday it has been and I pray to have this same body in case I need it for sex work tomorrow. 

I’ve gotten better about caring for myself though in some ways with regards to sex -- in cultivating working relationships with those I’d like to encounter again while trying to be as safe as possible with those helping me financially, who I may only see once in less than safe environments or circumstances. Which..has been rough. Unfortunately, I’ve had my share of experiences this year where I didn’t consent, which has looked many different ways. I know that can range from physically violent, drugged, intoxicated, changing one’s mind during sex, etc. Two instances I’m ok referring to occured or began at gay clubs in my area. One involved a man busting in the fucking restroom with me. He was drunk and like 60x stronger than me. That wasn’t protected; the other instance I’ll mention was when I was trashed. I knew this guy wanted to dance so we danced and I remember sitting down on the bench on a patio outside the club and then I woke up on the floor of my room, halfway under my air mattress naked. I was terrified because I didn’t know how I got home once I realized I was home, and my ass was really sore. I don’t know if that was protected or not. I didn’t pursue it further beyond not going back to that club. A few others have happened and it’s been a fucking trip to say the least. I am ok; I am dealing with it in the ways I can.

As a result, I’ve tested far more frequently than usual and started on PrEP ( Pre-exposure prophylaxis, Truvada). I had headaches and an upset stomach for several days which resulted in me simply stopping my dosage. I quickly learned those are things I needed to deal with as it beats the alternative of potentially getting HIV.  I started taking it at night rather than in the morning because I cant have headaches at my day job. Some staff members annoy me to great lengths and I can’t deal with that, headaches and shitting more than I ordinarily do. My side-effects have virtually gone away this second time, however. The only difference is the time I take it and that I take it with a vitamin D. 

I notice I’m taking care of myself when I moisturize my rff donor site and take my medication and it’s been two days I’ve skipped out on both which I need to not fucking do. I was having sex with someone yesterday and he was trying to penetrate me without any barriers. I swear I can be so stupid sometimes. I dont care for anal sex on rare occasions, and commonly I fucking hate it. It is not pleasurable for me at all... but the folks I sleep with, esp those who are helping me pay for life, want anal. I finally got up and was like hey, put this on and tried to make it sexy. It worried me I was pretty indifferent for many minutes before it occuring to me that this is my fucking life and this is just a random dick Ive never in my life seen who could have just about anything.. 

I’ve been preoccupied by thoughts that have troubled me but aren’t actually all that troubling in the bigger picture of my life. I mentioned I’ve been employed and it will be full time in a few weeks -- so through this new opportunity I’ve met someone who I’ve technically known for some time now. 

She reminds me of nobody I’ve ever had in my life and that’s kind of a huge inconvenience. I’ve replayed our interactions 8293432 times in hopes of finding what about her has been validating, or affirming, or whatever...that has allowed her to impact me in this way. When I first met her, I noticed her voice and her hair - both are unique in the sea of hair and voices present in our usual gatherings. Now things are rather dramatic and I’m not quite, but basically avoiding her. I’m sorry, I can’t actually like anyone and for certain reasons, I especially can’t like her. But yeah, unfortunately what I’m tripping about most as this 2017 year wraps up isn’t related to surgery or safety or any of that but developing feelings for a woman.

[projectqueer]

Thailand has become a massive drawcard for Chinese gay men looking to source PrEP. PrEP (pre-exposure prophylaxis) is a HIV preventative drug. When taken at the recommended dosage is highly effective at stopping the transmission of HIV.

The PrEP drug – Truvada – is available as an antiretroviral treatment for HIV in China. But it is not yet available as a HIV preventative drug.

A 2017 study revealed Chinese men who have sex with men (MSM) were highly likely to use PrEP if it were available to them. The rate of new HIV notifications in China grew in 2016 with China accounting for about 3% of new notifications globally. HIV is growing fastest amongst young MSM. A 2016 report showed HIV transmission rates among students at one city’s universities increased 43% annually in five years.

CLICK THE HEADER LINK TO READ THE FULL ARTICLE.

[shimclinic]

What Is the Difference Between PrEP and PEP? Everything you Need to Know

Significant strides in the fight to reduce HIV/AIDS infections have led to new medications that considerably reduce the chances of contracting the infection. PEP and PrEP are such medications that medical practitioners now give to people who may be exposed to the virus to reduce chances of getting the infection. The two almost work in the same way but are very much different.

Pre-Exposure Prophylaxis (PrEP)

PrEP is given to uninfected individuals who may be at a high risk of getting the infection. In addition, the regimen is given to individuals who may engage in sexual activities with HIV-positive individuals. Such people may be serodiscordant couples (this is where one is infected with the virus and the other is not), commercial sex workers and men who have sex with men.

The most common form of PrEP that is given to such people and the very first of its kind is Truvada. Truvada is a mix of tenofovir and emtricitabine. For the treatment to work, the drug is supposed to be taken on a daily basis.

According to the Centers for Disease Control and Prevention (CDC), if taken as recommended, Truvada can lower the chances of contracting HIV by 90% during sexual activity and by up to 70% through the use of injection drugs.

It is important to note that Truvada is not a vaccine for HIV, rather, a way to reduce the risk of contracting the virus. In addition, for it to work, the dosage must be strictly followed.

Post Exposure Prophylaxis (PEP)

CDC suggests that PEP should be given to HIV-negative people who suspect that they may have been exposed to HIV. The regimen should be given within 72 hours for it to work. Cases that may warrant the use of PEP include situations of condom breakage during sex, shared needles or cases of rape.

In addition, health workers are required to subscribe to PEP in the event that they get in contact with HIV-positive blood or bodily fluids through open wounds, mouths or eyes as well as situations where the health worker(s) may get cut with used medical equipment.

For PEP to be effective, the regimen, which is made up of two or three antiretroviral medication is to be taken daily for 28 days once or twice a day.

Conclusion

The two drugs named above aid to combat HIV infections before or after possible exposure. However, they are not 100% effective. This means that other preventive measures need to be used such as the use of condoms for protected sex in the case of those who prescribe for PEP. In addition, the dosages must be strictly followed for the treatment to be effective.

Lastly, even as research has shown that use of PrEP and PEP lowers the risk of contracting HIV, it does not reduce the risk of contracting other STIs such as syphilis, gonorrhea or chlamydia. This further asserts the importance of having protected sex and using condoms in the proper manner for protection against STIs and STDs. More information on PEP and PrEP can be accessed through STI clinics or HIV/AIDS testing clinics.

Original content here: https://www.shimclinic.com/blog/what-is-the-difference-between-prep-and-pep-everything-you-need-to-know

[genericforce-blog]

[erectiledysfunc]

male enhancement for men at rite aid

Contents

Enhancement pills gold

Sold dangerous male enhancement

Zyrexin sexual enhancement pills

Bit bigger extenze male enhancement

Keep your body in optimal shape with the help of these ExtenZe HT Higher Testosterone Dietary. Male Enhancement Supplement; Support of Increased Testosterone. image of GNC Mega Men Whole Body Vitapak Program – 30 ct.

The male dressed in black allegedly struck Baca with the longboard, suffered multiple gunshot wounds to his torso, and immediately received aid by other bystanders in the crowd. The complaint goes.

rev boost male enhancement pills Aluminum is found in most antacids. Vitamin C can increase how much aluminum the body absorbs. But it isn’t clear if this interaction is a big concern. Take vitamin C two hours before or four.

The NYPD is looking for three men who allegedly looted a Hell’s Kitchen. The raid on the 50th Street Rite Aid happened just after 11 p.m. Monday, one of the worst nights of the violent protests.

Product Name, Rockhard Weekend Male Enhancement Capsules – 4 ct. Package Count, 4. Container Type, blister pack. Form, Capsule. Dosage UOM.

men’s sexual health symptoms male enhancement elite melatonin male enhancement male enhancement pills side effect itching? male enhancement pills gold pill home brew for maximum male enhancement recipe what vitamins help with male enhancement The Vitamin shoppe sold dangerous male enhancement Pills: Lawsuit. June 11, 2019 – A man from Illinois has filed a products liability lawsuit against vitamin shoppe industries Inc. over claims the company sold a male enhancement pill that contained harmful toxins – including arsenic – that can cause severe injury and even death to consumers.Max Steel Male Enhancement Pills is improve body testosterone level and help to your sex power with your accomplice. Max Steel Male Enhancement is the best male upgrade supplements in the market. This enhancement is offering extra enjoyment and vitality during the sexual drivesThose people are no longer moving, not shouting, Red Pill Amazon staring at me pitifully. must not be the obnoxious thrill male enhancement pills wolf of our western knots.To reduce your risk for serious side effects, do not increase your dose. which may affect the ability of a male to father a child. Consult your doctor for more information.The substitution of synthetic melatonin by phytomelatonin in medical treatments. food-intake, retina physiology, sexual behavior, seasonal reproduction and. The role of melatonin in inmmuno-enhancement: potential application in cancer.The visionary, icily cool general Tokugawa Ieyasu-a man described in James Clavell’s fictionalized account Shogun as being.Signs of Sexual Dysfunction in Men and Women. Sexual dysfunction symptoms can manifest in different ways depending on the type and cause of dysfunction.ampallang for male sexual enhancement  · If you’re looking for the best male enhancement pills to change your sexual performance in just a matter of one or two hours, definitely consider buying Male Extra In my opinion, it’s the most potent product out on the market. For optimal results – stack Male.

Obviously, those cities were moved from other places by the monsters. Embroidered bamboo best male enhancement pills at rite aid saw the man paused for a long time before returning to the hall. Best Male Enhancement Pills At Rite Aid spell to fix erectile dysfunction Compares Sex Pills For Men how to fix low libido male.

Buy zyrexin sexual enhancement pills, World's Strongest sex pills, 10-count from Rite Aid online or in-stores. Orders of $34.99 or more ship.

Buy ExtenZe Male Sexual Enhancement Pills, Original Formula, 30 ct, from Rite Aid online or in-stores. Orders of $34.99 or more ship free. Shop ExtenZe today.

Descovy and Truvada-often referred to as PrEP, for “preexposure prophylaxis”-are approved for men at high risk of. which include Albertsons, CVS, Rite Aid, Vons, Walgreens, Walmart.

male enhancement pills side effect itching? But yes the Spartan Male Enhancement is a good option for the male power. It works without leaving any side effects on the user. Because the Spartan Male Enhancement Pills are the made up of a proprietary blend of all natural ingredients. Not only natural but also effective for male sexual health.

Surveillance video shows the suspect on April 18 walking into a Rite Aid on Nostrand Avenue in Sheepshead Bay, and beginning.

Men, do you believe that size matters Have you always wanted it to be a bit bigger extenze male enhancement can temporarily increase your size, enhance .

Buy ExtenZe Extended Release Maximum Strength Male Enhancement Gelcaps, 15 ct, from Rite Aid online. Orders of $34.99 or more ship free. Shop male.

I stopped taking these pills after second day. Beware of results. I wasted my money. Review by Sunil. Posted on 11/17/19.

An outbreak of severe hypoglycemia from a dietary supplement landed 17 men in the hospital last fall, but the FDA still doesn.

source https://www.erectiledysfunction-pills.com/male-enhancement-for-men-at-rite-aid/

[marketresearchnewsworld-blog]

Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market 2024: Overview, Trends, Opportunities, Impact of Drivers, Key Vendors, Types, Applications, Forecast by Focusing Companies

As per the research conducted by Fast. MR, the report titled “Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market, by Drugs (Truvada, Descovy, and Drugs in Pipeline 3/4), by Dosage Form (Oral and Topical), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) – Global Market Size, Development, Growth and Demand Forecast, 2014-2024” provides current as well as future analysis of the market by evaluating the major applications, advantages, trends, and challenges. The report dives deeper to produce useful insights into Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market such as major global regions and key competitors and strategies that can be used for the entry-level player too.

Overview

Pre-exposure prophylaxis (PrEP) is prescribed to people who are at very high risk of getting HIV through sex or the use of drug injection. The efficacy of PrEP is highly dependent on adherence. However, it does not protect against other sexually transmitted infections such as chlamydia, gonorrhea, and syphilis. The once-daily pill reduces the risk of getting HIV from sex by more than 90% and also reduces the risk among people who inject drugs by more than 70%. PrEP may either be taken orally, using a combination of two antiretroviral drugs (tenofovir plus emtricitabine) or topically as a vaginal gel containing tenofovir. Truvada (by Gilead Sciences, Inc.), which is available as a daily pill, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk has been increasingly used for several years. However, due to its high price (~$20,000 a year), many HIV-negative populations reluctant to take it.

Get Latest Sample for Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market @ https://www.fastmr.com/request-s/95

An increase in the prevalence of HIV infections is expected to propel the pre-exposure prophylaxis (PrEP) HIV drugs market growth.

An increase in the prevalence of HIV infections will lead to a rise in demand for PrEP drugs during the forecast period. For instance, according to the U.S. Department of Health & Human Services, there were approximately 37.9 Mn people living with HIV/AIDS across the globe in 2018. Of these, 36.2 million were adults, and 1.7 million were children (<15 years old). Further, in 2018, 23.3 million people with HIV (62%) have accessed antiretroviral therapy (ART) globally, an increase of 1.6 million since 2017, and up from 8 million in 2010.

In October 2019, USFDA approved Gilead Sciences, Inc. product- Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) for HIV-1 pre-exposure prophylaxis (PrEP), among adults and adolescents who are HIV-negative and considered to be at risk for sexually acquired HIV, except for those at risk for contracting it through vaginal sex. Such approval by the U.S. govt. is a part of ongoing efforts to end the HIV epidemic. Thus, expected to boost the growth of the pre-exposure prophylaxis (PrEP) HIV drugs market.

However, the cost of current PrEP HIV drugs made it difficult for HIV affected population to purchase. Thus the government of many countries are encouraging pharmaceutical companies to develop more PrEP drugs, including longer-lasting formulations, to continuously meeting the demand of the HIV-negative population at affordable prices.

Introduction of Merck’s experimental drug MK-8591, which wouldn’t need to be taken daily; Gilead’s next-generation PrEP drug, called GS-6207, which would also require far less frequent dosing than Truvada and generic version of Truvada by Teva during the forecast period, will help to cut down the price and have the opportunity to leverage the market share in PrEP HIV drugs Market during the forecast period.

Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market Regional Analysis

On the basis of region, North America is expected to show a leading position in the pre-exposure prophylaxis (PrEP) HIV drugs market. This is owing to rising adoption of new therapeutics and broader coverage of HIV drugs by various insurance companies in U.S. For instance, In May 2019, the Trump administration announced that it had negotiated a donation from Gilead Sciences Inc., for Truvada, in order to distribute the drug to 200,000 individuals each year for up to 11 years or until the generic drug becomes available. Thus, the cost incurs to distribute the drug will be cover by the government to make PrEP more accessible and affordable during the forecast period.

Developing countries including, Latin America and Africa, also witness spur growth of the pre-exposure prophylaxis (PrEP) HIV drugs market owing to the implementation of PrEP programs by the government. For instance, From December 2017, Brazil’s Ministry of Health started the provision of pre-exposure prophylaxis (PrEP) for HIV prevention in key higher-risk population groups through 35 sites across the country. This Brazilian program aims to offer PrEP to 54,000 people including, men who have sex with men (MSM), sex workers, and transgender people through Sistema Único de Saúde (SUS), Brazil’s National Health Service.

Moreover, in March 2016, the South African Ministry of Health also initiated a strategy to provide immediate antiretroviral treatment to all sex workers with HIV and to offer daily oral pre-exposure prophylaxis (PrEP) to HIV-negative sex workers to prevent them from acquiring the infection. Thus, continuous initiatives by the government to access PrEP to the affected population will boost the pre-exposure prophylaxis (PrEP) HIV drug market growth.

Key players operating in the pre-exposure prophylaxis (PrEP) HIV drugs markets include Gilead Sciences, Inc., Merck Sharp & Dohme Corp. Mylan Pharmaceuticals, Cipla Inc., Bristol-Myers Squibb Company, Genentech, Inc., and Teva Pharmaceuticals Industries Ltd.

Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market-Taxonomy

By Drugs

-Truvada

-Descovy

-Drugs in Pipeline 3/4

By Dosage Form

-Oral

-Topical

By Region

-North America

-Europe

-Asia Pacific

-Latin America

-Middle East and Africa

Browse Full Report With Table of Content @ https://www.fastmr.com/report/95/pre-exposure-prophylaxis-hiv-drugs-market

About US:

FAST.MR is a global market research and business-consulting organization that aims to provide a deep market insight to our clients, which helps them in better decision making in the dynamic environment. We have a team of highly qualified personnel that studies the market in depth to provide our clients with better strategies to stand out in the market.

Our report covers current market status, opportunities available in the market, growth plans, and emerging trends in order to cater to the evolving needs of the customers. We help businesses around the globe with operational improvements, technologies, emerging market trends which in-depth boost the company’s growth in the future. The reports prepared by us are customized according to the client’s needs. We inculcate high morale and ethics while preparing our report which helps in building long term relationships with our clients.

Contact Us:

Jason Lee

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: sales@fastmr.com

Website: www.fastmr.com

Follow Us – Facebook, Twitter, Linked In

[dinafbrownil]

New California Law May Expand Use Of HIV Prevention Drugs, With Caveats

SACRAMENTO, Calif. — Kellen Willhite was 24 when he learned he’d been exposed to HIV. What followed was, as he describes it, a second trauma: trying to obtain the drugs that could save him before it was too late.

In 2016, a day after Willhite and his then-boyfriend had engaged in unprotected sex, they visited the small offices of Golden Rule Services, a nonprofit community clinic about 7 miles south of the state Capitol.

“I had a gut feeling,” Willhite said. He wanted his boyfriend to be tested. The test result came back positive for HIV, and Willhite learned that he needed to start taking a medication known as post-exposure prophylaxis, or PEP.

Email Sign-Up

Subscribe to KHN’s free Morning Briefing.

Sign Up

Please confirm your email address below:

Sign Up

“I was terrified. I was crying because the clock was ticking. You have to start PEP within 72 hours of exposure,” Willhite said. A counselor at Golden Rule advised him about the drug and sent him to an emergency room, where he waited for a long time before being redirected to his primary care doctor for a prescription. The doctor was not in his office.

Eventually, Willhite got his prescription for the full month-long course of treatment, and later he moved to daily doses of anti-HIV pre-exposure prophylaxis, or PrEP. But he remembers the process as “a nightmare.”

A new California law, the first of its kind in the nation, is designed to avoid precisely the kind of stress Willhite endured after learning of his HIV exposure — and to eliminate obstacles for people looking for longer-term protection against the virus.

The law, SB-159, eliminates mandatory doctor visits and bars insurance companies from requiring prior authorization for the drugs. Pharmacists who take a special training course can dispense PEP and PrEP directly to patients without a physician’s prescription, beginning in July.

In signing the bill last month, California Gov. Gavin Newsom applauded the state legislature for “getting us close to ending HIV and AIDS for good.”

Among people working to halt the epidemic, the response has been more guarded. They say bypassing the prescription process is a welcome development, but it does not address all the barriers to access. Unless it is accompanied by cost control, education and relentless outreach to at-risk residents, they argue, it may not make the difference the bill’s supporters hope to see.

“We view this [bill] as one part of a broader access issue,” said Courtney Mulhern-Pearson, director of policy and strategy at the San Francisco AIDS Foundation. “It’s a piece of the puzzle.”

PrEP, marketed and sold by Foster City, Calif.-based Gilead Sciences under the brand name Truvada, is a single pill which, when taken daily, is up to 99% effective at reducing the risk of contracting HIV through sex, according to the Centers for Disease Control and Prevention. The prevention rate on PrEP among those who inject drugs is 74%. (The U.S. Department of Health and Human Services says that PEP, a combination of several different oral drugs, is very effective at preventing HIV infection post-exposure, but “not 100%.”)

Despite PrEP’s effectiveness, fewer than 40,000 of the estimated 220,000 to 240,000 state residents who could use it are taking the medication, according to the California Health Benefits Review Program, which analyzed the state law.

It estimated that PrEP and PEP usage would increase by 2% in the first year of the new law but, after that, barriers such as lack of reimbursement for patient counseling and lab tests could limit increases in its use.

Medical professionals who work with HIV pose tough questions about the law’s potential limitations: How many pharmacies will undertake the training necessary to act as dispensaries, and will they be evenly distributed around the state? What about people who can’t afford it? What will patients do when their maximum allowed prescription-free PrEP dosage — 60 days — runs out?

The 60-day limit was a compromise that induced the California Medical Association and other lobbies to drop their opposition to the legislation. It means those who wish to continue the regimen will have to make primary care visits before their 60-day supply runs out. Doctors say it’s important for people on Truvada to be monitored anyway, given the drug’s potential side effects on kidney and liver function and bone density.

State Sen. Scott Wiener (D-San Francisco), a co-sponsor of the law who revealed in 2014 that he uses PrEP every day to remain HIV-negative, noted that there are places in California where getting a prompt doctor’s appointment can be difficult. Being able to start PrEP or PEP without a prescription at least buys some time, he said.

One thing the law cannot address is how to get the drugs to the people at the highest risk: black and Latino men who have sex with men. Those two groups have the highest rates of new HIV cases nationally.

As the executive director of a nonprofit that offers free HIV testing, Clarmundo Sullivan says he works consistently with clients who aren’t even aware of the anti-HIV drug regimens PrEP and PEP, much less how to access them. (Mark Kreidler for California Healthline)

“This legislation is really, really important, but it’s slightly negligent in its approach,” said Clarmundo Sullivan, executive director of Golden Rule Services, where Kellen Willhite first learned he’d been exposed to HIV. “We have to do a better job of educating and reaching out to that high-risk community, to demystify what PrEP is. We’re still seeing very low uptake among people of color.”

An important factor behind the low use, and not just for people of color, is the cost of PrEP. The full price for Truvada is nearly $20,000 a year, and although Gilead and many states have programs in place to help defray the cost, a lot of people still have trouble affording it.

Willhite, who initially had a copay of $40 for PrEP with insurance he got through his mother, now has similar copays on an employer plan — and he knows he’s lucky. “I know people who are paying hundreds of dollars a month,” said Willhite, who now works at Golden Rule, three years after he first walked in there worried about HIV.

The month-long regimen of PEP runs between $600 and $1,000 without insurance.

Another financial hindrance, one built into the law, is a requirement to show you have tested negative for HIV within the past seven days before you can obtain PrEP without a prescription.

Golden Rule Services tests patients for free, as do many nonprofit clinics and county health departments in California. “But how many people in the community even know that?” Sullivan said. “Some of our clients are sharing with us that it’s costing them up to $250 to get an HIV test at certain places.”

There are other potential obstacles. A California Department of Insurance investigation found this year that some life, disability and long-term care insurance companies were denying coverage to people on PrEP, or hiking their premiums, which could have a chilling effect on its use.

In the end, said Golden Rule’s Sullivan, only aggressive outreach will lead to wider use of HIV-prevention medications. “It takes time, it takes money, it takes vulnerability, because you’re sharing very, very sensitive information,” he said. “The bureaucracy that’s involved has frustrated a lot of people.”

This KHN story first published on California Healthline, a service of the California Health Care Foundation.

from Updates By Dina https://khn.org/news/new-california-law-may-expand-use-of-hiv-prevention-drugs-with-caveats/

[brittanyyoungblog]

One Pill A Day May Keep HIV Away

The post One Pill A Day May Keep HIV Away was first seen on: https://www.hiv.meetpositives.com

If you are at risk of being infected with HIV, then the University of Arizona Campus Health Service has a drug that will help protect you from this risk. In 2012, the drug, named Truvada, became the first drug to be approved by the FDA in the reduction of risk associated with HIV infection.

Truvada is a combination of tenofovir disoproxil and emtricitabine and a form of pre-exposure prophylaxis, which is also known as PrEP. Cesar Egurrola, lead clinical coordinator at the UA Department of Medicine’s Petersen HIV Clinic, said when a PrEP medication is taken daily by HIV-negative patients, it prevents the transmission of HIV.”

This is especially useful to people who are at risk of infection and though they will have to be tested for HIV regularly, using the drug significantly lowers the infection risk.

“Patients who use PrEP must also undergo routine HIV and STD screenings and regularly visit their PrEP provider while on the medication. There is a similar method of using medication, called post-exposure prophylaxis or PEP, which helps prevent HIV transmission after a person is exposed to it. PEP is most often used after someone may have been exposed to HIV through sexual contact, sexual assault or from exposure to blood, often through needles. If PrEP can be compared to ‘the pill,’ PEP could be compared to ‘Plan B,’ with the exception that, for PEP, the 28-days course of treatment needs to be completed. And there is no weight maximum for PEP efficacy.”

Though the drug is effective, there are some requirements that need to be adhered to. Taking the PrEP drug is a daily affair. Apart from taking the medication daily, it is important that you take the medication 72 hours prior to the HIV exposure for effectiveness. This means that the PrEP and PEP users will have to carefully follow a dosage to be safe.

Both regimens need to be taken daily to provide maximal effectiveness. When taken daily, PrEP has a 92 percent success rate in the prevention of HIV transmission. Per the CDC, PEP is very effective in the prevention of transmission of HIV, but not 100 percent.”

Rising STD Cases

It is important to mention that the use of PrEP and PEP does not protect you from other sexually transmitted diseases and unwanted pregnancies. This is an important point because there is a rise in STD infection cases.

PrEP and PEP only protect against HIV. We continue to see high rates of Chlamydia and have seen more syphilis than in past years. According to the most recent Sexually Transmitted Disease Surveillance report by the Centers for Disease Control and Prevention in 2017, rates of STDs have been increasing across the country.

The report showed that over 1.7 million cases of Chlamydia in the U.S. were reported in 2017, an increase of 6.9 percent from the previous year. Reported cases of gonorrhea totaled over 555,600, which was over an 18 percent increase from 2016 and an increase of a little over 75 percent from a record low in 2009. The CDC report showed rates of syphilis rose 10.5 percent from 2016 to 2017, and 87.7 percent of those reported cases were men. Men make up the majority of people in Arizona who have HIV, according to the 2018 Arizona HIV/AIDS Epidemiology Supplemental Report from the Arizona Department of Health Services.”

Access To PEP and PrEP

People are becoming aware of these drugs and this is in some way helping lower the rate of infection. Though there are no massive campaigns through media channels to create awareness of the drugs, word of mouth is during quite well in spreading the news especially among students.

Word of mouth is an effective tool to encourage our students to come in to Campus Health to start PrEP and PEP, or even simply to ask questions, allowing them to become better informed about their options. Students have the opportunity to get the medications at reduced prices, and some are even able to get them without paying out-of-pocket.

There are patient-assistance programs and grants available that can offset the price of the medications. We utilize pharmacies that are well-versed in navigating these programs in order to provide our students with the lowest cost possible, regardless of insurance coverage or lack thereof.”

It is important to protect yourself when HIV is involved. You can always use protection and combine it with PEP and PrEP to ensure that the risk of infection is significantly lowered. For those living with HIV, the best option is to use a HIV dating site where HIV singles are looking for interesting singles like you. HIV dating has been around for a while and is an effective way to reduce cases of new infections.

from Meet Positives SMFeed 8 http://bit.ly/2V66eDS via IFTTT

[meetpositivesblog]

One Pill A Day May Keep HIV Away

The following article One Pill A Day May Keep HIV Away was first published on: HIV Meet Positives Blog

If you are at risk of being infected with HIV, then the University of Arizona Campus Health Service has a drug that will help protect you from this risk. In 2012, the drug, named Truvada, became the first drug to be approved by the FDA in the reduction of risk associated with HIV infection.

Truvada is a combination of tenofovir disoproxil and emtricitabine and a form of pre-exposure prophylaxis, which is also known as PrEP. Cesar Egurrola, lead clinical coordinator at the UA Department of Medicine’s Petersen HIV Clinic, said when a PrEP medication is taken daily by HIV-negative patients, it prevents the transmission of HIV.”

This is especially useful to people who are at risk of infection and though they will have to be tested for HIV regularly, using the drug significantly lowers the infection risk.

“Patients who use PrEP must also undergo routine HIV and STD screenings and regularly visit their PrEP provider while on the medication. There is a similar method of using medication, called post-exposure prophylaxis or PEP, which helps prevent HIV transmission after a person is exposed to it. PEP is most often used after someone may have been exposed to HIV through sexual contact, sexual assault or from exposure to blood, often through needles. If PrEP can be compared to ‘the pill,’ PEP could be compared to ‘Plan B,’ with the exception that, for PEP, the 28-days course of treatment needs to be completed. And there is no weight maximum for PEP efficacy.”

Though the drug is effective, there are some requirements that need to be adhered to. Taking the PrEP drug is a daily affair. Apart from taking the medication daily, it is important that you take the medication 72 hours prior to the HIV exposure for effectiveness. This means that the PrEP and PEP users will have to carefully follow a dosage to be safe.

Both regimens need to be taken daily to provide maximal effectiveness. When taken daily, PrEP has a 92 percent success rate in the prevention of HIV transmission. Per the CDC, PEP is very effective in the prevention of transmission of HIV, but not 100 percent.”

Rising STD Cases

It is important to mention that the use of PrEP and PEP does not protect you from other sexually transmitted diseases and unwanted pregnancies. This is an important point because there is a rise in STD infection cases.

PrEP and PEP only protect against HIV. We continue to see high rates of Chlamydia and have seen more syphilis than in past years. According to the most recent Sexually Transmitted Disease Surveillance report by the Centers for Disease Control and Prevention in 2017, rates of STDs have been increasing across the country.

The report showed that over 1.7 million cases of Chlamydia in the U.S. were reported in 2017, an increase of 6.9 percent from the previous year. Reported cases of gonorrhea totaled over 555,600, which was over an 18 percent increase from 2016 and an increase of a little over 75 percent from a record low in 2009. The CDC report showed rates of syphilis rose 10.5 percent from 2016 to 2017, and 87.7 percent of those reported cases were men. Men make up the majority of people in Arizona who have HIV, according to the 2018 Arizona HIV/AIDS Epidemiology Supplemental Report from the Arizona Department of Health Services.”

Access To PEP and PrEP

People are becoming aware of these drugs and this is in some way helping lower the rate of infection. Though there are no massive campaigns through media channels to create awareness of the drugs, word of mouth is during quite well in spreading the news especially among students.

Word of mouth is an effective tool to encourage our students to come in to Campus Health to start PrEP and PEP, or even simply to ask questions, allowing them to become better informed about their options. Students have the opportunity to get the medications at reduced prices, and some are even able to get them without paying out-of-pocket.

There are patient-assistance programs and grants available that can offset the price of the medications. We utilize pharmacies that are well-versed in navigating these programs in order to provide our students with the lowest cost possible, regardless of insurance coverage or lack thereof.”

It is important to protect yourself when HIV is involved. You can always use protection and combine it with PEP and PrEP to ensure that the risk of infection is significantly lowered. For those living with HIV, the best option is to use a HIV dating site where HIV singles are looking for interesting singles like you. HIV dating has been around for a while and is an effective way to reduce cases of new infections.